PEDIATRIC ONCOLOGY GROUP

该提案代表了支持继续参与 儿童肿瘤学小组(POG)。本次合作研究致力于 对化疗、免疫学和分子生物学的研究 治疗急性白血病和其他疾病的生物学方法 儿童的肿瘤性疾病。重大的无病存活率 在临床药理学方面取得了成就并做出了贡献， 肿瘤免疫学和癌症生物学。然而，真正的目标是 这些研究是通过治疗来根除肿瘤疾病。 研究正在设计中，以反映攻击的强度不断增加 在肿瘤细胞上。协作小组技术允许提示 一系列有希望的引线大小的评价 化疗。这些线索或新的方法通常是由 该小组在临床肿瘤学方面的工作成果。因此，一个完整的 议定书通常建议在新的议定书中探索新的途径。POG 在急性淋巴细胞免疫表型研究中发挥主导作用 白血病、白血病细胞中NTX多谷氨酸蓄积和N-myc 神经母细胞瘤的基因扩增与患者的相关性 结果，然后将它们纳入到设计的新治疗方案中 以提高癌症儿童的存活率。分部 加州大学圣地亚哥分校的儿科血液学/肿瘤学 有24年的合作经验(10年在CALGB，14年在POG) 临床试验。在过去的5年中，4个联合体成员 机构已经进入了332名患者的治疗和非治疗 治疗研究和卫星，211名患者。我们的调查人员 在12个委员会任职，设计/协调16个小组礼仪研究。 我们还为15个团体出版物/演示文稿做出了贡献。我们的 研究人员将继续设计和主持治疗方案，以及 在委员会任职。余博士的实验室将继续探索新的 团体使用的免疫治疗药物，并作为团体参考 实验室。我们计划继续积极参与所有阶段的工作 POG活动。

This proposal represents a request to support continued participation in the pediatric Oncology Group (POG). This cooperative research is devoted to the investigation of chemotherapeutic, immunological and molecular biological approaches to the treatment of acute leukemia and other neoplastic diseases of childhood. Significant disease free survival has been achieved and contributions have been made in clinical pharmacology, tumor immunology and biology of cancer. However the real objective of these studies is the eradication of neoplastic diseases by treatment. Studies are being designed to reflect an increasing intensity of attack on the neoplastic cell. The cooperative group technique permits prompt evaluation in series of reasonable size of promising leads in chemotherapy. These leads or new approaches are often suggested by the results of the group's own work in clinical oncology. Thus, a completed protocol often suggests new avenues to be explored in new protocols. POG led in the investigation in the immunophenotyping of acute lymphoblastic leukemia, NTX polyglutamates accumulation in leukemic cells, and N-myc gene amplication in neuroblastoma, correlated the findings with patient outcome, and then incorporated them in new treatment protocols designed to improve the survival of children with cancer. The Division of pediatric Hematology/Oncology at the University of California, San Diego has 24 years experience (10 years in CALGB and 14 in POG) in cooperative clinical trials. In the past 5 years the 4 consortium member institutions had entered 332 patients on both therapeutic and non- therapeutic studies and the satellites, 211 patients. Our investigators served on 12 committees, designed/coordinated 16 group protocol studies. We also contributed to 15 group publications/presentations. Our investigators will continue to design and chair therapeutic protocols,and serve on committees. Dr. Yu's laboratory will continue to explore new immunotherapeutic agents for Group use, and serve as the Group Reference Laboratory. We plan to continue our active participation in all phases of POG activities.